⏰ TL;DR (Too Long; Didn't Read)

<aside> ☝ KingoBio develops GraBeads, superior single-core magnetic beads that improve accuracy and efficiency in Next Generation Sequencing (NGS) and liquid biopsy applications.

</aside>

💡The Idea

• Next Generation Sequencing (NGS) is a high-throughput DNA sequencing technology that allows for rapid, accurate, and cost-effective sequencing of large amounts of genetic material.
• However, low performance of existing NGS beads (extraction and recovery rates ≤~50%) in combination with high loss and errors in current beads lead to consumptive diagnostic time
• KingoBio is introducing GraBeads, featuring uniform and stable single-core magnetic beads with superior magnetic properties, dispersion, high uniformity, and precise selectivity
• GraBeads are applicable for pathogen, protein, and nucleic acid separation and concentration

🥇Benefits

• High recovery rate (>20% higher than competitors)
• Excellent extraction rate (>15% higher than competitors)
• Uniform bead size (Cv of 5% or less)
• Superparamagnetic properties with strong magnetic performance
• High dispersity (PDI below 0.1)
• Wide range of applications including diagnostic kits, NGS, and early-stage infection detection

💵Business Model

• B2B sales to:
  1. Public sector
     1. Academic Research Institutions (Universities and colleges conducting advanced genetic research)
     2. Clinical Diagnostic Centers (Centers that use genetic sequencing for diagnosing diseases)
     3. Forensic Laboratories (Labs using genetic sequencing for criminal investigations and legal evidence)
     4. Hospitals
  2. Private sector
     1. Biotechnology companies (Firms specializing in the development of biotechnological products, including diagnostic kits)
     2. Molecular Diagnostics Companies (Firms focusing on molecular diagnostics, including genetic and genomic testing kits)
     3. Agricultural Biotechnology Firms (Companies applying genetic sequencing to improve crop and livestock breeds)
     4. NGS Analysis Institution (Companies that use genetic sequencing for diagnosing diseases)
     5. Pharmaceutical Companies (Companies involved in drug discovery and development)
• International expansion plans for US and Asia Pacific markets